 |
- Held a breakfast meeting with ex-UK Prime Minister Rishi Sunak during his visit to South Korea and discussed exchanges and AI cooperation between both nations.
- Anticipations that strengthening collaboration with important global figures and entities will enhance the corporate value of SK Networks.
SEOUL, South Korea, May 21, 2025 /PRNewswire/ -- SK Networks, aiming to evolve into an "AI-focused business holding company", is intensifying its initiatives to enhance collaboration and expand its operations through a global network. In this context, Sunghwan Choi, President & COO of SK Networks, who has been steering the tech-focused AI operations of the headquarters and its subsidiaries, reportedly met with former UK Prime Minister Sunak to explore methods for improving exchanges and corporate collaboration between the two nations.
As stated by company representatives, this Tuesday at The Shilla Seoul, President Choi and former Prime Minister Sunak held a breakfast meeting to exchange global trends and discuss AI and other technological collaborations between nations and corporations. SK Networks founded Hico Capital (now SK Networks Americas) in Silicon Valley, USA, in 2020. The company has been concentrating on global investments in and partnerships with technology firms centered around Hicosystem, the human network associated with future expansion sectors. The opportunity for an unexpected in-person meeting between Rishi Sunak, who visited South Korea for an international conference, and Sunghwan Choi is believed to stem from this network.
During this meeting, the pair shared perspectives on the current state of the global economy. They also discussed approaches to enhance relations between the two countries from the viewpoints of a politician and a business leader, as well as the possibilities and examples of AI collaboration at both national and corporate levels. In this context, President Choi presented innovative AI-based cases and global strategies from SK Group and SK Networks, expressing optimism that, in line with current trends, the company's AI endeavors would grow in the UK and across Europe, aiding the advancement of human civilization.
The industry has high expectations for the future potential of SK Networks, which is evolving into an AI company. In particular, NAMUHx held a showcase last month and received a favorable response from participants for its groundbreaking air purification and vital sign monitoring capabilities powered by AI. The brand intends to expand into the international market, including the US and Malaysia, following its official launch in Korea in July. It was established from the resources of SK Magic and is strategically overseen by SK Networks. NAMUHx manages its brand communication independently, emphasizing innovative technologies and services that differentiate it from SK Magic's existing products. PhnyX Lab, an AI startup comprised of Silicon valley talent, introduced a modular RAG (retrieval augmented generation) solution for the pharmaceutical sector named Cheiron at the end of last year and is preparing for market growth by forming tailored partnerships with businesses. The heads of SK Magic and PhnyX Lab attended the meeting alongside President Choi and former Prime Minister Sunak. Former Prime Minister Sunak stated, "AI holds the key to transforming the future of drug development. It promises new levels of speed and precision that could help hundreds of millions of patients around the world." He added, "Phynx Lab's Cherion looks like the kind of technology that has the potential to play an important part in this revolution."
SK Networks' efforts in collaborating and partnering with prominent global personalities and firms are expected to enhance its position as an AI enterprise.
- Held a breakfast meeting with ex-UK Prime Minister Rishi Sunak during his visit to South Korea and discussed exchanges and AI cooperation between both nations.
- Anticipations that strengthening collaboration with important global figures and entities will enhance the corporate value of SK Networks.
SEOUL, South Korea, May 21, 2025 /PRNewswire/ -- SK Networks, aiming to evolve into an "AI-focused business holding company", is intensifying its initiatives to enhance collaboration and expand its operations through a global network. In this context, Sunghwan Choi, President & COO of SK Networks, who has been steering the tech-focused AI operations of the headquarters and its subsidiaries, reportedly met with former UK Prime Minister Sunak to explore methods for improving exchanges and corporate collaboration between the two nations.
As stated by company representatives, this Tuesday at The Shilla Seoul, President Choi and former Prime Minister Sunak held a breakfast meeting to exchange global trends and discuss AI and other technological collaborations between nations and corporations. SK Networks founded Hico Capital (now SK Networks Americas) in Silicon Valley, USA, in 2020. The company has been concentrating on global investments in and partnerships with technology firms centered around Hicosystem, the human network associated with future expansion sectors. The opportunity for an unexpected in-person meeting between Rishi Sunak, who visited South Korea for an international conference, and Sunghwan Choi is believed to stem from this network.
During this meeting, the pair shared perspectives on the current state of the global economy. They also discussed approaches to enhance relations between the two countries from the viewpoints of a politician and a business leader, as well as the possibilities and examples of AI collaboration at both national and corporate levels. In this context, President Choi presented innovative AI-based cases and global strategies from SK Group and SK Networks, expressing optimism that, in line with current trends, the company's AI endeavors would grow in the UK and across Europe, aiding the advancement of human civilization.
The industry has high expectations for the future potential of SK Networks, which is evolving into an AI company. In particular, NAMUHx held a showcase last month and received a favorable response from participants for its groundbreaking air purification and vital sign monitoring capabilities powered by AI. The brand intends to expand into the international market, including the US and Malaysia, following its official launch in Korea in July. It was established from the resources of SK Magic and is strategically overseen by SK Networks. NAMUHx manages its brand communication independently, emphasizing innovative technologies and services that differentiate it from SK Magic's existing products. PhnyX Lab, an AI startup comprised of Silicon valley talent, introduced a modular RAG (retrieval augmented generation) solution for the pharmaceutical sector named Cheiron at the end of last year and is preparing for market growth by forming tailored partnerships with businesses. The heads of SK Magic and PhnyX Lab attended the meeting alongside President Choi and former Prime Minister Sunak. Former Prime Minister Sunak stated, "AI holds the key to transforming the future of drug development. It promises new levels of speed and precision that could help hundreds of millions of patients around the world." He added, "Phynx Lab's Cherion looks like the kind of technology that has the potential to play an important part in this revolution."
SK Networks' efforts in collaborating and partnering with prominent global personalities and firms are expected to enhance its position as an AI enterprise.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SK Networks President Sunghwan Choi encounters former UK Prime Minister
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
